-
公开(公告)号：US08221753B2
公开(公告)日：2012-07-17
申请号：US12751907
申请日：2010-03-31
IPC分类号： A61K39/395 , A61K39/00 , C07K16/00 , C07K16/18
CPC分类号： C07K16/30 , A61K31/282 , A61K31/337 , A61K31/4045 , A61K31/44 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K2039/505 , C07K16/2863 , C07K16/2896 , C07K16/3015 , C07K16/3038 , C07K16/3046 , C07K16/3061 , C07K16/3069 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , G01N33/57492 , G01N33/57496 , G01N33/6872 , G01N2333/70596 , G01N2333/71 , G01N2800/16 , G01N2800/164
摘要： The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
摘要翻译： 本申请涉及人源化和人源化/去免疫化抗内皮糖蛋白抗体及其抗原结合片段的组合物。 一个方面涉及在可变重链，可变轻链或两者的至少一个框架区的至少一个氨基酸残基中具有一个或多个修饰的抗体。 另一方面涉及结合内皮糖蛋白并抑制血管发生的抗体。 另一方面涉及人源化抗体的去免疫化以降低免疫原性。 另一方面涉及使用结合内皮糖蛋白的人源化和人源化/去免疫化抗体用于检测，诊断或治疗与内皮因子相关的疾病或病症，血管生成或其组合。
-
公开(公告)号：US08206715B2
公开(公告)日：2012-06-26
申请号：US13100990
申请日：2011-05-04
申请人： Justin Wong , Maximiliano Vasquez
发明人： Justin Wong , Maximiliano Vasquez
IPC分类号： A61K39/395 , C07K16/00 , C12P21/08
CPC分类号： C07K16/2866 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/11 , C12N15/63
摘要： Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
摘要翻译： 提供了结合CSF1R的抗体。 还提供能够形成结合CSF1R的抗体的抗体重链和轻链。 提供编码CSF1R抗体的多核苷酸。 还提供了编码抗体重链和灯链的多核苷酸。 提供使用抗CSF1R抗体的方法。 这些方法包括但不限于治疗类风湿性关节炎，骨丢失和多发性硬化症的方法。
-
公开(公告)号：US08101723B2
公开(公告)日：2012-01-24
申请号：US12614282
申请日：2009-11-06
申请人： Kyung Jin Kim , Wei-meng Zhao , Hangil Park , Maximiliano Vasquez
发明人： Kyung Jin Kim , Wei-meng Zhao , Hangil Park , Maximiliano Vasquez
IPC分类号： C12P21/08 , C07K16/00 , A61K39/00 , A61K39/395
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/565 , C07K2317/92 , G01N33/57492 , G01N2333/71
摘要： The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
摘要翻译： 本发明涉及对成纤维细胞生长因子受体2的单克隆抗体，包含其的药物组合物，以及治疗方法，包括向患者施用这种药物组合物。
-
公开(公告)号：US20110076263A1
公开(公告)日：2011-03-31
申请号：US12751907
申请日：2010-03-31
IPC分类号： A61K39/395 , C12Q1/68 , C07K16/18 , C07H21/04
CPC分类号： C07K16/30 , A61K31/282 , A61K31/337 , A61K31/4045 , A61K31/44 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K2039/505 , C07K16/2863 , C07K16/2896 , C07K16/3015 , C07K16/3038 , C07K16/3046 , C07K16/3061 , C07K16/3069 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , G01N33/57492 , G01N33/57496 , G01N33/6872 , G01N2333/70596 , G01N2333/71 , G01N2800/16 , G01N2800/164
摘要： The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
摘要翻译： 本申请涉及人源化和人源化/去免疫化抗内皮糖蛋白抗体及其抗原结合片段的组合物。 一个方面涉及在可变重链，可变轻链或两者的至少一个框架区的至少一个氨基酸残基中具有一个或多个修饰的抗体。 另一方面涉及结合内皮糖蛋白并抑制血管发生的抗体。 另一方面涉及人源化抗体的去免疫化以降低免疫原性。 另一方面涉及使用结合内皮糖蛋白的人源化和人源化/去免疫化抗体用于检测，诊断或治疗与内皮因子相关的疾病或病症，血管生成或其组合。
-
公开(公告)号：US20090181855A1
公开(公告)日：2009-07-16
申请号：US12210072
申请日：2008-09-12
CPC分类号： C07K16/18 , C07K16/005 , C07K16/40 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C40B40/10
摘要： The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.
摘要翻译： 本发明克服了通过专门设计具有定向序列和长度多样性的文库来生成抗体编码多核苷酸文库的已知方法中的不足之处。 这些图书馆旨在反映由人类免疫系统自然产生的免疫缺陷文库，并且基于通过检查公开可得到的人抗体序列数据库的合理设计。
-
公开(公告)号：US20090081239A1
公开(公告)日：2009-03-26
申请号：US12205760
申请日：2008-09-05
CPC分类号： C07K16/36 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76
摘要： The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.
-
公开(公告)号：US07365168B2
公开(公告)日：2008-04-29
申请号：US11102621
申请日：2005-04-08
申请人： Paul Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
发明人： Paul Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
CPC分类号： C07K16/00 , C07K16/082 , C07K16/249 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
-
68.发明授权Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis 有权通过诱变改变抗体的FcRn结合亲和力或血清半衰期公开(公告)号：US07361740B2
公开(公告)日：2008-04-22
申请号：US10822300
申请日：2004-04-09
CPC分类号： C07K16/249 , C07K16/00 , C07K16/082 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
摘要翻译： 本发明提供IgG类型的修饰抗体，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一个不同于 其存在于未修饰的抗体中，从而与未修饰的抗体相比改变对FcRn的结合亲和力和/或血清半衰期。
-
69.发明申请Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis 有权通过诱变改变抗体的FcRn结合亲和力或血清半衰期公开(公告)号：US20050276799A1
公开(公告)日：2005-12-15
申请号：US11102621
申请日：2005-04-08
申请人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
发明人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
CPC分类号： C07K16/00 , C07K16/082 , C07K16/249 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
摘要翻译： 本发明提供IgG类型的修饰抗体，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一个不同于 其存在于未修饰的抗体中，从而与未修饰的抗体相比改变对FcRn的结合亲和力和/或血清半衰期。
-
公开(公告)号：US06329511B1
公开(公告)日：2001-12-11
申请号：US09450520
申请日：1999-11-29
IPC分类号： C07K1600
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24
摘要： The invention provides humanized immunoglobulins that bind to and neutralize &ggr;-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.
摘要翻译： 本发明提供结合并中和γ-干扰素的人源化免疫球蛋白。 抗体可用于治疗免疫系统疾病，特别是自身免疫性疾病。
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.101 秒)
